Cardiff Oncology (CRDF) Operating Expenses (2011 - 2026)

Over the trailing twelve months to Jun 30, 2026, Cardiff Oncology reported Operating Expenses of $44.78 million, down 18.4% year-over-year; for FY2025, it came in at $49.55 million, up 0.4% from FY2024.

• Operating Expenses has increased in each of the last six years, with a five-year compound annual growth rate of 20.6% (FY2020 to FY2025).
• Going back by year, Operating Expenses was $49.33 million in FY2024 (+7.5%), $45.9 million in FY2023 (+13.9%), $40.29 million in FY2022 (+37.9%) and $29.21 million in FY2021 (+50.2%).
• The five-year range for quarterly Operating Expenses is $7.08 million (Q3 2021) to $14.9 million (Q2 2025).
• Year-over-year, Operating Expenses increased in four of the last seven quarters, with growth averaging 1.2%.
• The fastest year-over-year change in Operating Expenses over five years came in Q1 2022 (growth of 102.2%), and the weakest in Q4 2025 (a decline of 36.6%).